Colon Cancer Clinical Trial
Official title:
Phase III of the AB Prep Safety and Efficacy in Colon Cleansing
The purpose of this study is determine if the AB Prep (a 16 tablets colon cleansing prep), is an effective, and safe colon cleansing prep in preparation for colonoscopy, and severe constipation.
The available colon cleansing preps have issues with patient's tolerance( Abdominal pain,
nausea, vomiting), and as recently noted by the FDA safety issues such a change in EKG,
blood electrolytes requiring 72 hours to correct, and most recently PO4 nephropathy.
The AB Prep is a 16 tablets prep that has excellent patient's tolerance efficacy, with no
change in blood electrolytes or EKG. ( PhaseI (20 patients) and Phase II (200 patients)
The protocol that was used is as follows:
(IND application # 75,704)
Protocol design for testing the safety and efficacy of the AB Prep:
The AB Prep is a combination of 2 Reglan tablets (10mg each), 6 Dulcolax tablets, and 8
K-Phos Neutral tablets. The combination is given in two steps, four hours apart; the day
before the colonoscopy.
As before, the objective of this clinical trial is to examine the AB Prep first and foremost
for safety, and second for efficacy of colon cleansing.
The proposed trial is for One-Arm Study of subjects undergoing elective and therapeutic
colonoscopy.
Phase III: 400 patients, The selection will be random, the age probably ranging from 12 to
75 years old.
The patients will have a Pre, and post procedural EKG, comprehensive (Sodium, Potassium,
Creatinine, BUN, Calcium, Magnesium, Phosphate, Glucose), and vital signs.
The patients with severe constipation (One bowel movement per week or more) will not be
included in the study. (In our experience, those people required two days prep to achieve
colon cleansing).
The SRSS statistical program will be used for data collection and analysis:
The end point of the study is colon cleansing, adequate enough to perform colonoscopy. The
colon cleansing will be graded as follow:
1. Poor colon prep, unable to proceed with colonoscopy.
2. Able to do colonoscopy with, the colon cleansing labeled as:
A- Excellent, Totally cleansed B- Good, adequately cleansed, with need for irrigation.
In addition to efficacy, we would like to check for patient's satisfaction and compliance,
(Most common complaints that the patients tend to voice with the present approved colon
preps).
Patient's satisfaction data will be collected before the procedure and will be graded as
follow:
1. Totally satisfied with the Prep, without any complaints
2. Satisfied, with the following complaints (Nausea, vomiting, abdominal pain/cramping)
3. Unsatisfied with the Prep (Reasons!!!)
Patient's compliance will be graded as follow:
1. Compliant
2. Non compliant(Reasons).
The prep instruction will be as follows REPARATION FOR COLONOSCOPY
FIVE DAYS before your procedure:
1. If you take COUMADIN or PLAVIX, we recommend that you stop these medications. You must
contact your primary care physician or cardiologist for specific instructions. You may
restart these medications again after the procedure unless otherwise instructed.
2. If you have DIABETES and take medication to control your blood sugar, contact your
primary care physician or diabetes doctor for instructions about how to take your
diabetes medication while preparing for this procedure.
3. Stop taking iron or multivitamins that contain iron.
4. Avoid the use of aspirin and aspirin-like medications such as ibuprofen, Advil and
Aleve. These medicines may increase your risk of bleeding after polyp removal.
5. Start a low-roughage diet and do not eat corn or raw vegetables. You may re-start your
usual diet after the procedure.
TWO DAYS before the procedure:
1. Take 2 tablets of Dulcolax at 8:00 PM.
ONE DAY before the procedure:
1. Begin a clear liquid diet at breakfast and continue this diet until 4 hours before your
procedure. A clear liquid diet includes: water, tea, black coffee, clear broth, apple
juice, white grape juice, Gatorade, soda, Jell-O. Do not eat or drink anything red,
including red Jell-O. Do not drink milk. Do not use sugar-free drinks. All patients,
including those with DIABETES, should be sure they get enough sugar during this time.
2. At 8:00 AM, take One Reglan(10mg) tablet, 2 Dulcolax tablets, and 4 tablets of K-PHOS
NEUTRAL. Drink three glasses of water/juice SLOWLY over 1 hour. The laxative effect
begins in about 2 hours. BE SURE TO DRINK AT LEAST 3 GLASSES OF WATER OR JUICE AFTER
TAKING EACH DOSE OF THE prep.( Each Glass =350cc)
3. At 12:00 Noon, Take 2 Dulcolax tablets and 4 tablets of K-PHOS NEUTRAL, along with 3
glasses of water/Juice.(Each glass =350cc).
ON THE DAY of your procedure:
1. Take all of your usual medicines and 1 tablet of Reglan (10mg). Do Not Take Coumadin,
Plavix, or Aspirin. If you take INSULIN, take 1/2 your usual dose.
2. If you have a medical condition requiring antibiotics before or after procedures, we
will determine whether they are needed for your colonoscopy.
3. STOP CLEAR LIQUIDS 4 HOURS BEFORE YOUR PROCEDURE (except for small amount of water with
medications). DO NOT EAT OR DRINK ANYTHING UNTIL AFTER YOUR PROCEDURE.
4. Wear loose-fitting, comfortable clothes.
5. Read the consent form. You will be asked to sign the form before your procedure.
Please bring these things WITH YOU to your procedure:
1. A list of all of your medications, including the doses
2. Your identification or insurance card
3. The name and phone number of your escort.
AFTER your procedure:
1. You will be monitored in the Endoscopy Unit recovery area for 20-30 minutes.
2. You may have some abdominal bloating after the procedure. It should resolve within an
hour.
4. You may eat your normal diet after the procedure.
5. You may return to work the day after the procedure.
HELPFUL HINTS FOR PATIENTS UNDERGOING COLONOSCOPY
1.Use moist wipes (baby wipes) instead of toilet paper.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT03457454 -
Reducing Rural Colon Cancer Disparities
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03390907 -
Hybrid APC Assisted EMR for Large Colon Polyps
|
N/A | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04079478 -
The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
|
||
Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05147545 -
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
|
N/A | |
Recruiting |
NCT05026268 -
The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis
|
N/A | |
Not yet recruiting |
NCT03277235 -
Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02730702 -
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
|
||
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Recruiting |
NCT02526836 -
Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer
|
Phase 2/Phase 3 |